GeoVax Labs (GOVX) Research & Development (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Research & Development of $3.1 million for Q2 2026, down 34.22% year-over-year from $4.7 million in Q2 2025, and up 3.88% quarter-over-quarter from $3.0 million in Q4 2025.
GeoVax Labs (GOVX) Research & Development (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Research & Development for 17 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development fell 34.22% year-over-year to $3.1 million; the TTM figure through Jun 2026 stood at $15.9 million (down 36.73% YoY), while the FY2025 annual figure was $18.1 million, down 23.58% from the prior year.
- Research & Development improved to $3.1 million in Q2 2026 per GOVX's latest filing, from $3.0 million in the prior quarter.
- Across five years, Research & Development topped out at $7.6 million in Q4 2024 and bottomed at $1.3 million in Q2 2022.
- Historically, Research & Development has averaged $4.4 million across 5 years, with a median of $4.4 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development sank 70.8% — and 2023, when it jumped 261.06%.
- GeoVax Labs' Research & Development stood at $3.8 million in 2022, then surged by 65.59% to $6.2 million in 2023, then climbed by 22.04% to $7.6 million in 2024, then slumped by 60.64% to $3.0 million in 2025, then climbed by 3.88% to $3.1 million in 2026.
- Business Quant data shows GOVX's Research & Development at $3.1 million in Q2 2026, $3.0 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 97.90 Mn |
| 10 | GeoVax Labs | 2.88 Mn | -267,341.61 | - | 3.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.11 Mn |
| Dec 31, 2025 | 2.99 Mn |
| Sep 30, 2025 | 5.04 Mn |
| Jun 30, 2025 | 4.73 Mn |
| Mar 31, 2025 | 5.35 Mn |
| Dec 31, 2024 | 7.61 Mn |
| Sep 30, 2024 | 7.40 Mn |
| Jun 30, 2024 | 4.28 Mn |
| Mar 31, 2024 | 4.43 Mn |
| Dec 31, 2023 | 6.23 Mn |
| Sep 30, 2023 | 6.95 Mn |
| Jun 30, 2023 | 4.72 Mn |
| Mar 31, 2023 | 2.82 Mn |
| Dec 31, 2022 | 3.76 Mn |
| Sep 30, 2022 | 2.72 Mn |
| Jun 30, 2022 | 1.31 Mn |
| Mar 31, 2022 | 1.33 Mn |
| Dec 31, 2021 | 12.89 Mn |
| Sep 30, 2021 | 1.22 Mn |
| Jun 30, 2021 | 832,835.00 |